US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment
14/08/2026 13:03
US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment Aug 14 (Reuters) - The U.S. Food and Drug Administration has approved a radioactive agent from Lantheus Holdings LNTH.O for use in brain scans to help assess patients for Alzheimer's disease, the company said on Friday.
(Reporting by Kunal Das and Puyaan Singh in Bengaluru; Editing by Devika Syamnath)
Recent news on Lantheus Holdings
See all newsMedia: Banks vie for $4.25 billion debt financing to back Lantheus deal - Bloomberg News
US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment (updated)
US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment
Lantheus Holdings, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lantheus Q2 revenue rises 2.7%, beats estimates